Skip to main content

Table 1 Patient demographics and clinical characteristics

From: Effects of antirejection therapies for early subclinical acute rejection in renal transplant protocol biopsies

 

Group A (n = 166)

Group B (n = 103)

p-value

Recipient sex, male

103 (62.5)

65 (63.1)

0.862

Recipient age, years

34 (11–63)

35 (13–48)

0.470

Donor sex, male

69 (41.6)

50 (48.5)

0.263

Donor age, years

50 (42–62)

53 (40–65)

0.723

HLA-A/B mismatch

1.69 ± 1.02

1.83 ± 1.07

0.278

HLA-DR mismatch

0.87 ± 0.64

0.96 ± 0.63

0.279

CNI (TAC)

90 (54.2)

41 (39.8)

0.022

ABO-incompatible

36 (21.7)

24 (23.3)

0.757

Plasmapheresis

17 (10.3)

18 (17.8)

0.078

Rituximab

36 (21.7)

22 (21.4)

0.949

WIT, min

3 (3–4)

4 (3–5)

0.100

CIT, min

66 (55–87)

65.5 (52–91)

0.333

Initial urine output, min

13 (7–28)

15 (9–29)

0.337

CMV infection within 3 months

47 (28.3)

52 (50.5)

 < 0.001

IS decreased after CMV infection

61.7% (29/47)

66.7% (34/51)

0.608

3-month protocol biopsy

 Normal

166 (100)

0 (0.0)

 

 Borderline changes

0 (0.0)

83 (80.6)

 

 Subclinical acute rejection

0 (0.0)

20 (19.4)

 
  1. Data are presented as n (%), mean ± standard deviation, or median (interquartile range) unless otherwise indicated.
  2. HLA human leukocyte antigen, CNI calcineurin inhibitor, WIT warm ischemia time, CIT cold ischemia time, TAC tacrolimus, CMV cytomegalovirus, IS immunosuppression agents